



Cite this: *RSC Adv.*, 2017, 7, 44470

Received 24th July 2017
 Accepted 10th September 2017

DOI: 10.1039/c7ra08136g

rsc.li/rsc-advances

Bicyclo[6.1.0]nonyne and tetrazine amino acids for Diels–Alder reactions†

Xu Li,^a Zhengkun Liu^a and Shouliang Dong *^{ab}

Here we report a general method for the *de novo* synthesis of a bicyclo[6.1.0]nonyne group containing an amino acid, and used Marfey's reagent for chiral analysis. This unnatural amino acid offered exceptional reactivity in the inverse electron demand Diels–Alder cycloaddition with tetrazine containing amino acids. The subsequent selective labeling of living cells at low dye concentrations demonstrated the usefulness of the new amino acid for future imaging studies. This work also laid the foundation for introducing this unnatural amino acid into peptides based on the solid-phase synthesis method.

Introduction

The selective and efficient labeling of biomolecules under physiological conditions is still hard to achieve with traditional biochemical or molecular biology tools. Since bioorthogonal chemical reactions can be performed without any interference to the biological system, there is considerable interest in their utilization to label and track small molecules on live cells.¹ Commonly used bioorthogonal reactions that meet these criteria are Staudinger ligations,² copper(I)-catalyzed azide–alkyne cycloaddition,³ and strain-promoted azide–alkyne cycloaddition.⁴ However, the derivatives of these reactions have poor water solubility or difficulty in synthesizing large quantities. Indeed, improving the reaction kinetics and the biocompatibility of the current reactions needs to be further studied, and the development of new bioorthogonal reactions with high reactivity is urgent. Currently, some reports demonstrated that tetrazines can react rapidly and specifically with strained alkenes to form stable adducts in inverse electron demand Diels–Alder (IED-DA) cycloaddition reactions.^{5–7} This chemistry is orders of magnitude faster than the classical cycloadditions and has been used in live cell labeling.^{8,9}

Very recently, with the development of IED-DA cycloaddition reaction in bioorthogonal field, the method for specific labeling of proteins in complex biological systems is the currently attractive area. The most popular technique in the modification of proteins is based on the introduction of genetical unnatural amino acids by using bioorthogonal tRNA/tRNA-synthetase

pairs.^{10,11} Inspired by recent advances in IED-DA cycloaddition reactions, the repertoire of genetically encoded chemical reactive amino acids grew considerably.¹² And a set of new dienophilic amino acids were synthesized and incorporated into proteins in *E. coli* and mammalian cells through suppressing the amber stop codon.^{13–15}

Many of the synthetic unnatural amino acids were connected by a ligand or a linker between these functional tags and natural amino acid groups.^{16–18} This method provides a easy way to synthesis a wide range of unnatural amino acids with diverse side chains, but this kind amino acids also have many deficiencies, such as unstability, difficult to handle, and complex structure may affecting the function. While the *de novo* synthesis of unnatural amino acids provides another way to overcome this defects, and many method had developed.^{19–21} But the *de novo* synthesis of unnatural amino acids for IED-DA reactions was almost no literature reports. The toolbox of unnatural amino acids was further expanded by our recent report, in which tetrazine group was connected directly to the benzene ring of phenylalanine and a tetrazine-containing amino acid was synthesized.²² The tetrazine amino acid has shown to be stable enough to be used for peptide modification and live cell labeling.

In this study, based on the known diversity of hydrophilic dienes, we sought to *de novo* synthesize an unnatural amino acid containing a hydrophilic diene group. As a reaction partner for the tetrazines, bicyclo[6.1.0]nonyne (BCN) group was selected as a model dienophile substrate for the unnatural amino acid synthesis, which possessed a higher reactivity than many hydrophilic dienes because of its enhanced cyclopropane fusion reactivity.²³ Moreover, unlike other strained alkenes, BCN reacted with tetrazine to give a single product of defined stereochemistry. Besides, the compound was easily obtained in a highly straightforward process through cyclopropanation of 1,5-cyclooctadiene.

^aInstitute of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou University, 222 Tianshui South Road, Lanzhou 730000, China. E-mail: dongsl@lzu.edu.cn

^bKey Laboratory of Preclinical Study for New Drugs of Gansu Province, 222 Tianshui South Road, Lanzhou 730000, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra08136g



Results and discussion

Synthesis and characterizations of L-BCN-containing amino acid


Just as the literature reported,^{23–25} compound **6** can be synthesized in four steps started by the dropwise addition of ethyl diazoacetate to excess 1,5-cyclooctadiene in the presence of rhodium acetate, to give a mixture of diastereomeric compounds **exo-3** and **endo-3**. Next, the individual stereoisomer **exo-3** was selected because of its higher yield, and was converted into the corresponding hydroxyalkyne product by the reduction of the ester group, bromination, and elimination, to give the compound BCN group.

Compound **11** can be synthesized in five steps started by the oxidation of alcohol of BCN to the aldehyde under Swern conditions,²⁶ followed by the Strecker reaction to nitrile.²⁷ One key step in the reaction was the hydrolysis of the intermediate nitrile **8** with 2 M NaOH to afford BCN amino acid. While by contrast, in experimenting we found that the hydrolysis of the intermediate nitrile **8** with 6 M HCl and 10% aqueous H₂SO₄ led to an entirely conversion of **8** into by-product ketone amino acid. Attempts of enantioselective hydrolysis of **8** with recombinant nitrilase from *Arabidopsis thaliana* (EC 3.5.5.1) failed. At last, the amino acid **9** was acetylated with Ac₂O and the resulting Ac-BCN was enantiomerically resolved with kidney acylase I to produce L-BCN amino acid (Scheme 1).²⁸


To test whether the configuration of the product was single, the N α -(2,4-dinitro-5-fluorophenyl)-L-alanine amide (FDAA) reagent was selected for chiral analysis,²⁹ and the results confirmed the enantiomeric purity of the compound. Compound **11** was sufficiently stable for prolonged storage at 20 °C and did not undergo any structural changes upon stirring in the presence of PBS solution.

Synthesis and characterizations of tetrazine-containing amino acid

Next, we aimed to synthesize tetrazine-containing amino acids (Scheme 2). We all knew that 1,2,4,5-tetrazines were pretty reactive toward water, which made them unsuitable for



Scheme 1 Synthetic route of L-BCN amino acid **11**. (a) Rh₂(OAc)₄ (0.5% eq.), rt, 25 h. (b) LiAlH₄ (0.8 eq.), 0 °C, 30 min, 93.6%. (c) Br₂ (1.1 eq.), 0 °C, 20 min, 92.0%. (d) KOtBu (3 eq.), 80 °C, 2 h, 65.0%. (e) (COCl)₂ (1.3 eq.), DMSO (2.5 eq.), Et₃N (6 eq.), –78 °C, 5 h, 95%. (f) (LiHMDS) (1.0 M in THF, 1.2 eq.), –40 °C, acetone cyanohydrin (2 eq.), rt, 12 h, 78%. (g) 2 M NaOH, 80 °C, 2 h, 38.1%. (h) Ac₂O (2.5 eq.), 1 M NaOH, rt, 2 h, 54%. (i) kidney acylase I, 37 °C, 2 days, 25%.



Scheme 2 Synthetic route of tetrazine amino acid **13** and **14**, and Boc-protected tetrazine amino acid **15**, and the IED-DA reaction of **13** and **14** with L-BCN amino acid **11** (a) (i) acetamidine hydrochloride (4 eq.), N₂H₄ (40 eq.), S (1 eq.), rt, 22 h; (ii) CH₃COOH, NaNO₂ (5 eq.), 0 °C, 30 min, 64.9%. (b) Phosphate buffered solution (PBS), rt, 30 min. (c) (i) Formamidine acetate (4 eq.), N₂H₄ (40 eq.), S (1 eq.), rt, 22 h; (ii) CH₃COOH, NaNO₂ (5 eq.), 0 °C, 30 min, 64.9%. (d) Boc₂O (2 eq.), 1 : 1 dioxane/H₂O (V/V), NaHCO₃ (2.5 eq.), 0 °C, 8 h, 72.3%. (e) Phosphate buffered solution (PBS), rt, 30 min.

bioconjugation. While, the stability of tetrazines can be dramatically improved by the substitution with aromatic groups. Our previously synthesized tetrazine amino acid **13** showed excellent stability in PBS and biological media, with little or no decomposition after prolonged exposure at room temperature, but was unstable in 20% piperidine/DMF.²² In general, tetrazines, which was substituted with electron donating groups like alkyl, tended to be more stable with slower cycloaddition kinetics.³⁰ According to the above summarized theory, we added a methyl in tetrazine of compound **13** to give another tetrazine amino acid (*S*)-2-amino-3-(4-(6-methyl-1,2,4,5-tetrazin-3-yl) phenyl) propanoic acid **14**, which demonstrated a good balance of solution stability and fast reaction kinetics.

The tetrazine amino acid **14** was synthesized in a way similar to compound **13**. Compound **14** was prepared starting from the commercially available 4-cyano-L-phenylalanine with acetamidine hydrochloride and anhydrous hydrazine in the presence of elemental sulfur. The initial product dihydrotetrazine derivative was oxidized to the tetrazine by treating with sodium nitrite in acetic acid. Moreover, compound **14** showed excellent stability in 20% piperidine/DMF with little or no decomposition observed after prolonged exposure at room temperature (see Fig. S2†), a prerequisite for peptide synthesis *via* an Fmoc synthetic strategy.

Kinetic experiments between BCN-containing amino acid and tetrazine-containing amino acids

We have synthesized a BCN-containing amino acid and tetrazine-containing amino acids. Alternatively, we sought to directly select the reaction of the BCN amino acid and tetrazine amino acids as bioorthogonal chemical “handles” for amino acid coupling *via* the IED-DA reactions. The rate constants of the reactions between BCN amino acid and tetrazines, a prerequisite *in vivo* applications, was determined by manual



mixing under the pseudo-first-order conditions. By following the exponential decay of the tetrazine absorbance at 523 nm upon reaction with a 10–100 fold excess of BCN, we determined the rate constants of the reactions between BCN amino acid and tetrazine **13** as $k_2 = (437 \pm 13) \text{ M}^{-1} \text{ s}^{-1}$ (see Fig. S3†). Under the same conditions, the rate constants of the reactions between BCN amino acid and tetrazine **14** was determined with UV/vis spectroscopy following the decay in the absorption of tetrazine derivative at 527 nm. The results showed that $k_2 = (1.45 \pm 0.05) \text{ M}^{-1} \text{ s}^{-1}$ (see Fig. S4†). Obviously, the reactions between two tetrazine amino acids and BCN amino acid were so reactive and suitable for rapid biological labeling.

L-BCN-containing amino acid in the epidermoid carcinoma cells labeling

Specific labeling of living cell was one of the most valuable applications in bioorthogonal chemistry.^{31,32} To prove the possible biological application of the L-BCN amino acid, we chose to label epidermal growth factor receptors (EGFR), which played an important role in cancer-cell signaling and was considered as the key target for therapeutic inhibition, with the anti-EGFR monoclonal antibody cetuximab. Commercially available cetuximab was marked with tetrazine amino acid derivative and fluorescein dye rhodamine group. A431 epidermoid carcinoma cells can overexpress EGFR, which bound antibody cetuximab specifically and efficiently.³³

Based on the commercial availability of numerous amine-reactive fluorophores, the BCN-fluorophore probes were utilized. And the free amine of BCN amino acid **11** was conjugated to a commercially available near-infrared (NIR) fluorophore Cy5.5 to label cells pretargeted with tetrazine-bearing antibodies. Furthermore, we chose the more reactive Boc-protected tetrazine **13** for the cell-labeling studies, which was serum-stable and reacted rapidly with strained dienophiles BCN.

A431 cancer cells were first incubated with modified cetuximab for 45 min in serum. Then, the cells were washed and incubated with BCN-Cy5.5 for 10 min in 100% fetal bovine




Fig. 1 Compound **11** reacted with Boc-protected tetrazine amino acid to label cancer cells. Cancer cells A431, which overexpressed EGFR, were exposed to the Cetuximab antibodies modified with tetrazine and 5-carboxyfluorescein (green). In the next step, the pretargeted cells were labeled with a BCN bearing a fluorophore such as Cy5.5 (red).




Fig. 2 (A) Fluorescent microscope images of A431 epidermoid carcinoma cells after pretargeting Cetuximab antibodies modified with 5-carboxyfluorescein and tetrazine and subsequent labeling with BCN-Cy5.5. From left to right, bright field and fluorescence from Rhodamine channel and Near-IR channel, respectively. Images of control experiments were also taken. (B) Control experiment with 5-carboxyfluorescein modified cetuximab and BCN-Cy5.5. (C) Control experiment with tetrazine modified cetuximab and BCN-Cy5.5.

serum (FBS). After being rewashed, the cells were imaged immediately by confocal microscopy (see Fig. 1). We can observe cellular changes in rhodamine channel and NIR channel, respectively. A431 cells were incubated with rhodamine modified cetuximab and BCN-Cy5.5 as control experiment 1. A431 cells were incubated with tetrazine modified cetuximab and BCN-Cy5.5 as control experiment 2. The results showed that the antibody could be visualized clearly in rhodamine channel and the covalently bound tetrazine-VT680 could be monitored apparently in the NIR channel. Cells incubated with the control antibody, which contained rhodamine but not tetrazine, showed no NIR labeling after exposure to **11**. While control experiment 2, the antibody containing tetrazine instead of rhodamine, resulted in no rhodamine fluorescence (see Fig. 2), suggesting that BCN-Cy5.5 conjugate did not react with other cellular components.

These experiments demonstrated the specificity and sensitivity of the reaction between BCN-containing amino acid and tetrazine-modified antibody in the complex biological living cells. Consequently, we concluded that this BCN-containing amino acid of using IED-DA reaction was suitable for *in vitro* labeling experiments, and might also provide an effective way to label cells in the complex intracellular environment.

Experimental

All the experimental procedures and supporting figures are reported in the ESI.†

Conclusions

In conclusion, we reported a general method for *de novo* synthesis of a BCN group containing amino acid, and used



Marfey's reagent for chiral analysis, which laid the foundation for being introduced into peptides based on the solid-phase synthesis method. Moreover, as a reaction partner for the BCN amino acid, we also *de novo* synthesized another tetrazine containing amino acid **14** in a way similar to compound **13**, which was synthesized in our previous work. We demonstrated that the reactions of BCN amino acid and tetrazine amino acids can be used as a bioorthogonal chemical "handle" for amino acid coupling *via* the IED-DA reaction. Finally, the high reaction rate of BCN amino acid and tetrazine amino acids was suitable for cancer cell labeling under physiological conditions. Our future efforts will focus on the incorporation of this BCN amino acid site-directly in peptide modification.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors want to thank Prof. Lingyun Mu for the Fluorescent microscope experiments.

References

- 1 E. M. Sletten and C. R. Bertozzi, *Angew. Chem., Int. Ed.*, 2009, **48**, 6974–6998.
- 2 B. L. Nilsson, L. L. Kiessling and R. T. Raines, *Org. Lett.*, 2000, **2**, 1939–1941.
- 3 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, *Angew. Chem.*, 2002, **114**, 2708–2711.
- 4 J. C. Jewett, E. M. Sletten and C. R. Bertozzi, *J. Am. Chem. Soc.*, 2010, **132**, 3688–3690.
- 5 M. L. Blackman, M. Royzen and J. M. Fox, *J. Am. Chem. Soc.*, 2008, **130**, 13518–13519.
- 6 L. Törk, G. Jiménez-Osés, C. Doubleday, F. Liu and K. Houk, *J. Am. Chem. Soc.*, 2015, **137**, 4749–4758.
- 7 S. Kotha, A. S. Chavan and D. Goyal, *ACS Comb. Sci.*, 2015, **17**, 253–302.
- 8 N. K. Devaraj, R. Weissleder and S. A. Hilderbrand, *Bioconjugate Chem.*, 2008, **19**, 2297–2299.
- 9 H. Wu, J. Yang, J. Šečkutė and N. K. Devaraj, *Angew. Chem., Int. Ed.*, 2014, **53**, 5805–5809.
- 10 C. H. Kim, J. Y. Axup and P. G. Schultz, *Curr. Opin. Chem. Biol.*, 2013, **17**, 412–419.
- 11 W. H. Zhang, G. Otting and C. J. Jackson, *Curr. Opin. Struct. Biol.*, 2013, **23**, 581–587.
- 12 T. Plass, S. Milles, C. Koehler, J. Szymański, R. Mueller, M. Wießler, C. Schultz and E. A. Lemke, *Angew. Chem., Int. Ed.*, 2012, **51**, 4166–4170.
- 13 E. Kaya, M. Vrabel, C. Deiml, S. Prill, V. S. Fluxa and T. Carell, *Angew. Chem., Int. Ed.*, 2012, **51**, 4466–4469.
- 14 J. L. Seitchik, J. C. Peeler, M. T. Taylor, M. L. Blackman, T. W. Rhoads, R. B. Cooley, C. Refakis, J. M. Fox and R. A. Mehl, *J. Am. Chem. Soc.*, 2012, **134**, 2898–2901.
- 15 Z. Yu, Y. Pan, Z. Wang, J. Wang and Q. Lin, *Angew. Chem., Int. Ed.*, 2012, **51**, 10600–10604.
- 16 K. Lang, L. Davis, J. Torres-Kolbus, C. Chou, A. Deiters and J. W. Chin, *Nat. Chem.*, 2012, **4**, 298–304.
- 17 S. Schneider, M. J. Gattner, M. Vrabel, V. Flügel, V. López-Carrillo, S. Prill and T. Carell, *ChemBioChem*, 2013, **14**, 2114–2118.
- 18 K. Lang, L. Davis, S. Wallace, M. Mahesh, D. J. Cox, M. L. Blackman, J. M. Fox and J. W. Chin, *J. Am. Chem. Soc.*, 2012, **134**, 10317–10320.
- 19 S. Kotha, *Acc. Chem. Res.*, 2003, **34**, 342–351.
- 20 M. A. T. Blaskovich, *J. Med. Chem.*, 2016, **59**, 10807–10836.
- 21 K. Undheim, *Amino Acids*, 2008, **34**, 357–402.
- 22 Z. Ni, L. Zhou, X. Li, J. Zhang and S. Dong, *PLoS One*, 2015, **10**, e0141918.
- 23 J. Dommerholt, S. Schmidt, R. Temming, L. J. Hendriks, F. P. Rutjes, J. van Hest, D. J. Lefeber, P. Friedl and F. L. Van Delft, *Angew. Chem., Int. Ed.*, 2010, **49**, 9422–9425.
- 24 M. T. Taylor, M. L. Blackman, O. Dmitrenko and J. M. Fox, *J. Am. Chem. Soc.*, 2011, **133**, 9646–9649.
- 25 A. Borrmann, S. Milles, T. Plass, J. Dommerholt, J. M. Verkade, M. Wießler, C. Schultz, J. van Hest, F. L. van Delft and E. A. Lemke, *ChemBioChem*, 2012, **13**, 2094–2099.
- 26 A. J. Mancuso, S.-L. Huang and D. Swern, *J. Org. Chem.*, 1978, **43**, 2480–2482.
- 27 G. H. Chu, M. Gu, B. Gerard and R. E. Dolle, *Synth. Commun.*, 2004, **34**, 4583–4590.
- 28 S. Dong, L. Merkel, L. Moroder and N. Budisa, *J. Pept. Sci.*, 2008, **14**, 1148–1150.
- 29 R. Bhushan and H. Brückner, *Amino Acids*, 2004, **27**, 231–247.
- 30 M. R. Karver, R. Weissleder and S. A. Hilderbrand, *Bioconjugate Chem.*, 2011, **22**, 2263–2270.
- 31 N. K. Devaraj and R. Weissleder, *Acc. Chem. Res.*, 2011, **44**, 816–827.
- 32 K. Lang and J. W. Chin, *Chem. Rev.*, 2014, **114**, 4764–4806.
- 33 H.-S. Han, N. K. Devaraj, J. Lee, S. A. Hilderbrand, R. Weissleder and M. G. Bawendi, *J. Am. Chem. Soc.*, 2010, **132**, 7838–7839.

